AAA
MYGN icon

Adams Asset Advisors’s Myriad Genetics MYGN Stock Holding History

Adams Asset Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,301
Closed -$1.42M – 102
2017
Q3 		$1.42M Sell
39,301
-48,906
-55% -$1.39M 0.19% 54
2017
Q2 		$2.28M Hold
88,207
– – 0.34% 47
2017
Q1 		$1.69M Hold
88,207
– – 0.24% 53
2016
Q4 		$1.47M Buy
+88,207
New +$1.6M 0.19% 57

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Adams Asset Advisors's MYGN Position: Q4 2017 in Review

Adams Asset Advisors sold out of Myriad Genetics (MYGN) in Q4 2017, closing a stake of 39,301 shares — an estimated $1.42M sold.

Adams Asset Advisors first reported a position in MYGN in Q4 2016 and held it in 4 quarters. The position peaked at $2.28M in Q2 2017. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • Adams Asset Advisors reported no remaining Myriad Genetics position as of Q4 2017 after selling out during the quarter.
  • Adams Asset Advisors sold 39,301 Myriad Genetics shares in Q4 2017, an estimated $1.42M.
  • Adams Asset Advisors first reported a position in Myriad Genetics in Q4 2016 and held it in 4 quarters.
  • Adams Asset Advisors's Myriad Genetics position peaked at $2.28M in Q2 2017.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on Adams Asset Advisors's 13F filing for Q4 2017, filed 11 Jan 2018.